Latest
Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Cholangiocarcinoma targeted therapy widens past chemotherapy
FGFR2 inhibitor maturity, IDH1 inhibitor use, HER2-targeted therapy entry, and IO combinations are restructuring biliary tract cancer management.
By signal pillar
Clinical readouts
4Bispecific T-cell engager uptake in lymphoma is constrained by cytokine-release-syndrome management capacity
Bispecific T-cell engagers in B-cell lymphoma are demonstrating strong response rates in late-line settings, but commercial uptake is limited by the cytokine-release-syndrome management infrastructure required for safe administration. The constraint is more binding than the clinical evidence base suggests.
KRAS G12C resistance patterns are reshaping second-line NSCLC sequencing
Resistance mechanisms emerging from sotorasib and adagrasib post-progression sampling are converging on a finite set of pathways. The implications for second-line decision-making and combination design are starting to land in clinic.
TROP2 ADC class read-throughs from Q1 2026 readouts
The TROP2 antibody-drug conjugate class has multiple late-stage assets reading out in overlapping breast cancer and NSCLC populations. Q1 2026 readouts have started to differentiate the class on toxicity profile and biomarker dependency rather than on bulk efficacy.
Antibody-drug conjugates are reshaping the HER2-low breast cancer setting
T-DXd's expansion into HER2-low has changed second-line decision-making, and the ADC class is delivering further candidates that are likely to redefine biomarker-driven sequencing across breast cancer subtypes.
Regulatory
1Market access & reimbursement
1Scientific
15Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Cholangiocarcinoma targeted therapy widens past chemotherapy
FGFR2 inhibitor maturity, IDH1 inhibitor use, HER2-targeted therapy entry, and IO combinations are restructuring biliary tract cancer management.
Glioblastoma therapy options evolve past temozolomide and TTFields
Tumour-treating fields maturity, IDH-mutant glioma vorasidenib approval, and emerging mechanism-targeted programs are reshaping glioma management.
Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Tumor-infiltrating lymphocyte therapy expands past melanoma
TIL therapy approval in metastatic melanoma is opening pathways into cervical and other solid tumour indications.
Bispecifics reshape relapsed lymphoma care
T-cell engaging bispecifics are settling into routine third-line and later care for diffuse large B-cell and follicular lymphoma.
Radioligand therapy as a routine oncology option
Targeted radioligand therapy is settling into prostate and neuroendocrine cancer treatment as a routine, infrastructure-bound modality.
PROTAC oncology pipeline is transitioning from concept to commercial reality
Targeted protein degradation programs (PROTACs and molecular glues) in oncology have moved from early-stage proof-of-concept to multiple late-stage assets with pivotal readouts in the next 24 months. The mechanism's promise of drugging previously undruggable targets is closer to commercial validation than at any prior point.
Antibody-drug conjugates as a routine option
ADC-class therapies are normalising into solid-tumour treatment plans across breast, lung, and bladder cancer.
Bispecifics expanding the oncology toolkit
T-cell engagers and bispecific antibodies continue to broaden the oncology toolkit across haematological and solid tumours.
Cell therapy as routine haematology
CAR-T and other cell therapies are normalising into haematology practice.